Clinically significant CYP2C inhibition by noscapine but not by glucosamine

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 343-346

  Rosenborg, S ^a   Stenberg, M ^a   Otto S ^a   Stervall, J ^a   Masquelier, M ^a   Yue, Q Y ^b   Bertilsson, L ^a   Eliasson, E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTROX; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2C19; GLUCOSAMINE; LOSARTAN; NOSCAPINE; OMEPRAZOLE; QUININE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTICOAGULANTS; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; FEMALE; GLUCOSAMINE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; NOSCAPINE; OMEPRAZOLE; PHENOTYPE; WARFARIN; YOUNG ADULT;

EID: 77955926982     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.107     Document Type: Article

References (24)

1. Swedish Medical products Agency. Reported Adverse Drug Reactions during 2008. Information from the MpA 20, 37 (2009).
2. Wadelius, M. et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
3. Ohlsson, S., Holm, L., Myrberg, O., Sundström, A. & Yue, Q.Y. Noscapine may increase the efect of warfarin. Br. J. Clin. Pharmacol. 65, 277-278 (2008).
4. Zhong-Ze, F., Yan-Yan, Z., Guang-Bo, G., Hong, H., Si-Cheng, L. & Ling, Y. Time-dependent inhibition (tDI) of CYp3A4 and CYp2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br. J. Clin. Pharmacol. 69, 193-199 (2010).
5. Scordo, M.G., Melhus, H., Stjernberg, E., Edvardsson, A.M. & Wadelius, M. Warfarin-noscapine interaction: a series of four case reports. Ann. Pharmacother. 42, 448-450 (2008).
6. Myhr, K. [Noscapine and warfarin-a potentially dangerous interaction]. Tidsskr. Nor. Laegeforen. 129, 540 (2009).
7. Karlsson, M.O., Dahlström, B., Eckernäs, S.A., Johansson, M. & Alm, A.T. pharmacokinetics of oral noscapine. Eur. J. Clin. Pharmacol. 39, 275-279 (1990).
8. Ronge, S. The Swedish National Register of Dispensed Prescriptions (Xplain, Apoteket AB, stockholm, sweden, 2009)
9. Us National Institutes of Health. A study of Noscapine HCI (CB3304) in patients With Relapsed or Refractory Multiple Myeloma. Accessed 30 January 2010.
10. Us National Institutes of Health. study of Noscapine for patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy. Accessed 30 January 2010.
11. Rozenfeld, V., Crain, J.L. & Callahan, A.K. possible augmentation of warfarin efect by glucosamine-chondroitin. Am. J. Health. Syst. Pharm. 61, 306-307 (2004).
12. Yue, Q.Y., Strandell, J. & Myrberg, O. Concomitant use of glucosamine potentiates the efect of warfarin (poster abstract). Drug Saf. 29, 911 (2006).
13. Knudsen, J.F. & Sokol, G.H. potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy 28, 540-548 (2008).
14. Therapeutic Goods Administration (tGA) DoHaA, Australian Government. Interaction between glucosamine and warfarin. Aust. Adv. Drug Reactions Bull. 27, 3 (2008).
15. Christensen, M. et al. The Karolinska cocktail for phenotyping of fve human cytochrome p450 enzymes. Clin. Pharmacol. Ther. 73, 517-528 (2003).
16. Yasar, U. et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYp2C9 genotype. Clin. Pharmacol. Ther. 71, 89-98 (2002).
17. Lindh, J.D., Holm, L., Andersson, M.L. & Rane, A. Infuence of CYp2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65, 365-375 (2009).
18. Böttiger, Y. Use of omeprazole sulfone in a single plasma sample as a probe for CYp3A4. E.J.Clin.Pharmacol. 62, 621-625 (2006).
19. Ye, K. et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl. Acad. Sci. U.S.A. 95, 1601-1606 (1998).
20. Landen, J.W. et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 62, 4109-4114 (2002).
21. Barken, I., Geller, J. & Rogosnitzky, M. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res. 28, 3701-3704 (2008).
22. Flockhart, D.A. Drug Interactions: Cytochrome p450 Drug Interaction table, 25 January 2009. Accessed 14 January 2010.
23. Stearns, R.A., Chakravarty, P.K., Chen, R. & Chiu, S.H. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome p4502C and 3A subfamily members. Drug Metab. Dispos. 23, 207-215 (1995).
24. Mega, J.L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).